CA2506719A1 - Treatment of chronic heart failure - Google Patents

Treatment of chronic heart failure Download PDF

Info

Publication number
CA2506719A1
CA2506719A1 CA002506719A CA2506719A CA2506719A1 CA 2506719 A1 CA2506719 A1 CA 2506719A1 CA 002506719 A CA002506719 A CA 002506719A CA 2506719 A CA2506719 A CA 2506719A CA 2506719 A1 CA2506719 A1 CA 2506719A1
Authority
CA
Canada
Prior art keywords
group
substituted
alkyl
chf
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506719A
Other languages
English (en)
French (fr)
Inventor
Lin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506719A1 publication Critical patent/CA2506719A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002506719A 2002-12-20 2003-12-11 Treatment of chronic heart failure Abandoned CA2506719A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/325,420 2002-12-20
US10/325,420 US20040122067A1 (en) 2002-12-20 2002-12-20 Treatment of chronic heart failure
PCT/US2003/039410 WO2004060489A2 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Publications (1)

Publication Number Publication Date
CA2506719A1 true CA2506719A1 (en) 2004-07-22

Family

ID=32593758

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506719A Abandoned CA2506719A1 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Country Status (7)

Country Link
US (1) US20040122067A1 (https=)
EP (1) EP1581308A2 (https=)
JP (1) JP2006514051A (https=)
CA (1) CA2506719A1 (https=)
MX (1) MXPA05006628A (https=)
PL (1) PL375893A1 (https=)
WO (1) WO2004060489A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CN101646440A (zh) * 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CA2955577A1 (en) 2014-07-30 2016-02-04 Teijin Pharma Limited Xanthine oxidase inhibitor
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) * 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
KR100818845B1 (ko) * 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
US7417038B1 (en) * 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
EP1158989B1 (en) * 1999-03-09 2007-06-20 Anker, Stefan Use of inhibitors of endotoxin for the treatment of cachexia

Also Published As

Publication number Publication date
WO2004060489A2 (en) 2004-07-22
JP2006514051A (ja) 2006-04-27
PL375893A1 (en) 2005-12-12
EP1581308A2 (en) 2005-10-05
MXPA05006628A (es) 2005-09-30
US20040122067A1 (en) 2004-06-24
WO2004060489A3 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
JP6584391B2 (ja) 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
EP2814486B1 (en) Antiviral drugs for treatment of arenavirus infection
US7872037B2 (en) Antiviral drugs for treatment of arenavirus infection
US20040122067A1 (en) Treatment of chronic heart failure
US8461177B2 (en) Antiviral drugs for treatment of arenavirus infection
US8759400B2 (en) Histone deacetylase inhibitors for enhancing activity of antifungal agents
MX2009007680A (es) Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
US11813261B2 (en) HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
EP3054954A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CN101466435A (zh) Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
US20210077487A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
CN101420958A (zh) 共投与腺苷a1受体拮抗剂和抗惊厥药
CA3157656A1 (fr) Utilisation de nictotinamide mononucleotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoide et compositions correspondantes
US8841333B2 (en) Methods for treating nephrolithiasis
EP3068400A1 (en) Methods for reducing uric acid levels using barbiturate derivatives
US20040254228A1 (en) Treatment of chronic heart failure
CA2808492A1 (en) Antifungal agents and uses thereof
KR20000005115A (ko) 이미다졸유도체를함유하는함유하는항-hiv조성물
US11554123B2 (en) Compositions and methods for reactivating latent HIV-1 infections
US8871746B2 (en) Antiviral drugs for treatment of arenavirus infection
WO2012057343A1 (ja) Ｎａｄ（ｐ）ｈオキシダーゼ阻害剤、酸化ストレス疾患治療薬、酸化ストレス疾患治療方法及びスクリーニング方法
Lahlou et al. Dose-dependent therapeutic effects of trans-3-methoxy-β-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension
HK1204949B (en) Antiviral drugs for treatment of arenavirus infection
JP2015024967A (ja) ドナー特異的輸血の効果増強薬

Legal Events

Date Code Title Description
FZDE Discontinued